Comparative Pharmacology
Head-to-head clinical analysis: HYDROCODONE versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCODONE versus QDOLO.
HYDROCODONE vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system, inhibiting ascending pain pathways and altering perception of pain.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
5-10 mg orally every 4-6 hours as needed for pain; maximum 60 mg/day
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
Terminal elimination half-life is approximately 3.8-4.5 hours in adults; may be prolonged in hepatic or renal impairment.
Clinical Note
moderateHydrocodone + Torasemide
"The risk or severity of adverse effects can be increased when Hydrocodone is combined with Torasemide."
Clinical Note
moderateHydrocodone + Etacrynic acid
"The risk or severity of adverse effects can be increased when Hydrocodone is combined with Etacrynic acid."
Clinical Note
moderateHydrocodone + Furosemide
"The risk or severity of adverse effects can be increased when Hydrocodone is combined with Furosemide."
Clinical Note
moderateHydrocodone + Bumetanide
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Renal (67%) as conjugated morphine and normorphine, norhydrocodone, and hydromorphone; fecal (negligible).
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category D/X
Category C
Opioid Agonist
Opioid Agonist
"The risk or severity of adverse effects can be increased when Hydrocodone is combined with Bumetanide."